According to a new 13D filing with the SEC, billionaire Andreas Halvorsen‘s Viking Global may be deemed to have “dispositive power” over 75 million shares of Axovant Sciences Ltd. (NYSE:AXON), which amass 75.6% of the company’s outstanding stock. This is due to Dr. Andrew Lo’s appointment to the Board of Directors of Axovant Sciences, upon which Viking Global gained the right to override certain decisions made by the company, including dispositions of common shares, though only with the support of two other major shareholders of Axovant Sciences. Viking Global doesn’t currently beneficially own any shares or securities of Axovant Sciences (NYSE:AXON).
Axovant Sciences, previously known as Roivant Neurosciences, is a biopharmaceutical company engaged in producing therapeutics to help treat people who suffer from dementia. Over the past 12 months, the company’s stock is down by 30.35%. Recently, Leering Swann and HC Wainwright reiterated their ‘Buy’ ratings on Axovant Sciences’ stock. For the company’s fiscal year 2016 ended March 31, the company reported a net loss of $133.1 million and a loss per share of $1.41.
There were 11 smart money investors in our database long Axovant Sciences (NYSE:AXON) at the end of March, out of which Peter Kolchinsky’s RA Capital Management held the most valuable position, worth around $57.4 million. The second-biggest stake was reported by Jacob Gottlieb’s Visium Asset Management, valued at $48.1 million. Some other hedge funds with similar bullishness included D E Shaw, founded by David E. Shaw, and Joseph Edelman’s Perceptive Advisors.
Among the new investors of Axovant Sciences (NYSE:AXON) during the first quarter were Anders Hove and Bong Koh’s VHCP Management, which initiated the largest position, worth $2.1 million. Hal Mintz’s Sabby Capital, Mike Vranos’ Ellington, and Jeremy Green’s Redmile Group also added the stock to their portfolios during the quarter.
You can access the original SEC filing by clicking here.
Follow Sio Gene Therapies Inc. (NASDAQ:SIOX)
Follow Sio Gene Therapies Inc. (NASDAQ:SIOX)
Ownership Summary Table
|Name||Sole Voting Power||Shared Voting Power||Sole Dispositive Power||Shared Dispositive Power||Aggregate Amount Owned Power||Percent of Class|
|Viking Global Investors||0||0||0||75,000,000||75,000,000||75.6%|
|Viking Global Performance||0||0||0||75,000,000||75,000,000||75.6%|
|Viking Global Equities||0||0||0||75,000,000||75,000,000||75.6%|
|Viking Global Equities II||0||0||0||75,000,000||75,000,000||75.6%|
|VGE III Portfolio Ltd||0||0||0||75,000,000||75,000,000||75.6%|
|Viking Long Fund GP||0||0||0||75,000,000||75,000,000||75.6%|
|Viking Long Fund Master Ltd||0||0||0||75,000,000||75,000,000||75.6%|
|Viking Global Opportunities GP||0||0||0||75,000,000||75,000,000||75.6%|
|Viking Global Opportunities Portfolio GP||0||0||0||75,000,000||75,000,000||75.6%|
|Viking Global Opportunities Illiquid Investments Sub-Master||0||0||0||75,000,000||75,000,000||75.6%|
|O. Andreas Halvorsen||0||0||0||75,000,000||75,000,000||75.6%|
|David C. Ott||0||0||0||75,000,000||75,000,000||75.6%|
|Daniel S. Sundheim||0||0||0||75,000,000||75,000,000||75.6%|
Follow Andreas Halvorsen's Viking Global
Page 1 of 21 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a)
|Axovant Sciences Ltd.|
|(Name of Issuer)|
|Common Shares, $0.00001 par value|
|(Title of Class of Securities)|
55 Railroad Avenue
Greenwich, Connecticut 06830
|July 8, 2016|
|(Date of Event which Requires Filing of this Statement)|
If the filing person has previously filed a statement on Schedule
13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box. ¨
Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7
for other parties to whom copies are to be sent.
(Continued on following pages)
(Page 1 of 21 Pages)
* The remainder of this cover page shall be filled
out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent
amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this
cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).